Cognizant CapEx decreased by 1.3% to $76.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.3%, from $77.00M to $76.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows relatively stable performance with a 0.8% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $75.00M | $51.00M | $65.00M | $120.00M | $43.00M | $79.00M | $90.00M | $98.00M | $68.00M | $73.00M | $78.00M | $79.00M | $79.00M | $56.00M | $83.00M | $77.00M | $67.00M | $67.00M | $77.00M | $76.00M |
| QoQ Change | — | -32.0% | +27.5% | +84.6% | -64.2% | +83.7% | +13.9% | +8.9% | -30.6% | +7.4% | +6.8% | +1.3% | +0.0% | -29.1% | +48.2% | -7.2% | -13.0% | +0.0% | +14.9% | -1.3% |
| YoY Change | — | — | — | — | -42.7% | +54.9% | +38.5% | -18.3% | +58.1% | -7.6% | -13.3% | -19.4% | +16.2% | -23.3% | +6.4% | -2.5% | -15.2% | +19.6% | -7.2% | -1.3% |